IL-15 mutants having antagonist activity
US9493533B2 · kind B2 · utility
14Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2010 |
| Grant date | Nov 15, 2016 |
| Priority date | — |
| Expiry date | Aug 9, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor α-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLII68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.